

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/247954 A1

(43) International Publication Date
01 December 2022 (01.12.2022)

(51) International Patent Classification:

A61K 31/165 (2006.01) A61P 35/00 (2006.01)
A61K 31/4188 (2006.01)

(21) International Application Number:

PCT/CN2022/095983

(22) International Filing Date:

30 May 2022 (30.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/194,585 28 May 2021 (28.05.2021) US

(71) Applicant: NATUREWISE BIOTECH & MEDICALS
CORPORATION [CN/CN]; 6F., No.36, Sec. 3, Bade Rd.,
Songsan Dist., Taipei City 105, Taiwan (CN).

(72) Inventors: HUANG, Chung-Yang; 6F., No.36, Sec. 3,
Bade Rd., Songsan Dist., Taipei City 105, Taiwan (CN).
HOU, Chia-Chung; 6F., No.36, Sec. 3, Bade Rd., Song-
shan Dist., Taipei City 105, Taiwan (CN).

(74) Agent: GE CHENG & CO., LTD; Level 10, Tower E3,
The Towers, Oriental Plaza, No.1, East Chang An Avenue,
Dongcheng District, Beijing 100738 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITION AND METHOD FOR TREATING A DRUG-RESISTANT CANCER

(57) Abstract: A combination and method for treating a Temozolomide (TMZ) -resistant cancer patient, which comprises a combination of TMZ and an isoform-selective HDAC8 inhibitor, such as BMX at an effective relative ratio to overcome TMZ resistance by enhancing TMZ-mediated cytotoxic effect by downregulating the β -catenin/c-Myc/SOX2 signaling pathway and upregulating WT-p53 mediated MGMT inhibition is provided.

WO 2022/247954 A1